Literature DB >> 8486938

The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies.

E Rosenqvist1, E A Høiby, E Wedege, B Kusecek, M Achtman.   

Abstract

The 5C protein is expressed by the strain of Neisseria meningitidis (44/76) used for production of the Norwegian meningococcal group B outer membrane vesicle vaccine and is included in the final formulation of this vaccine. The immunoglobulin G antibody response to 5C stimulated by vaccination, systemic meningococcal disease, and carriage was measured using ELISAs with synthetic liposomes as antigen and by immunoblotting. Increased levels of IgG were found in paired sera from all three groups. The antibodies were bactericidal to meningococci of serogroups A and B that expressed large amounts of 5C but not to meningococci expressing smaller amounts. There was a linear correlation between bactericidal titer and units of IgG to 5C.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486938     DOI: 10.1093/infdis/167.5.1065

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine.

Authors:  Ray Borrow; Ingeborg S Aaberge; George F Santos; T Lynn Eudey; Philipp Oster; Anne Glennie; Jamie Findlow; E Arne Høiby; Einar Rosenqvist; Paul Balmer; Diana Martin
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

2.  Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.

Authors:  E Wedege; K Bolstad; A Aase; T K Herstad; L McCallum; E Rosenqvist; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

3.  Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates.

Authors:  Jeannette N Williams; Paul J Skipp; C David O'Connor; Myron Christodoulides; John E Heckels
Journal:  Infect Immun       Date:  2009-09-08       Impact factor: 3.441

4.  Surface antigen analysis of group B Neisseria meningitis outer membrane by monoclonal antibodies: identification of bactericidal antibodies to class 5 protein.

Authors:  M G Danelli; N M Batoreu; M D Lacerda; C R Ferreira; J D Cardoso; J M Peralta; C E Frasch
Journal:  Curr Microbiol       Date:  1995-09       Impact factor: 2.188

5.  Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.

Authors:  E Wedege; E A Høiby; E Rosenqvist; G Bjune
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

6.  Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine.

Authors:  L G Milagres; M C Gorla; C T Sacchi; M M Rodrigues
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

7.  Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.

Authors:  B Haneberg; R Dalseg; E Wedege; E A Høiby; I L Haugen; F Oftung; S R Andersen; L M Naess; A Aase; T E Michaelsen; J Holst
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

8.  Phase variation mediates reductions in expression of surface proteins during persistent meningococcal carriage.

Authors:  Mohamed Alamro; Fadil A Bidmos; Hannah Chan; Neil J Oldfield; Emma Newton; Xilian Bai; Jack Aidley; Rory Care; Claire Mattick; David P J Turner; Keith R Neal; Dlawer A A Ala'aldeen; Ian Feavers; Ray Borrow; Christopher D Bayliss
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

9.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

10.  Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.

Authors:  Jo Anne Welsch; Dan Granoff
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.